Table 2 Relationship between TFPI2 mRNA and clinico-pathological parameters
From: TFPI2 suppresses breast cancer progression through inhibiting TWIST-integrin α5 pathway
Parameters | Number of patients | TFPI2 mRNA expression | P value | |
|---|---|---|---|---|
Low (< median) | High (≥ median) | |||
Number | 50 | 25 | 25 | |
Age | ||||
< Mean (47) | 27 | 14 | 13 | 0.777 |
≥ Mean (47) | 23 | 11 | 12 | |
Tumor size | ||||
T1–2 | 26 | 18 | 8 | 0.005* |
T3–4 | 24 | 7 | 17 | |
Nodal status | ||||
N0–1 | 23 | 14 | 9 | 0.156 |
N2–3 | 27 | 11 | 16 | |
Metastasis | ||||
M0 | 32 | 20 | 12 | 0.018* |
M1 | 18 | 5 | 13 | |
Pathological stage | ||||
I-II | 29 | 19 | 10 | 0.010* |
III-IV | 21 | 6 | 15 | |